Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$4.02 USD
-0.12 (-2.90%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.04 +0.02 (0.50%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Arbutus Biopharma (ABUS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$5.25 | $7.00 | $4.00 | 26.81% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Arbutus Biopharma comes to $5.25. The forecasts range from a low of $4.00 to a high of $7.00. The average price target represents an increase of 26.81% from the last closing price of $4.14.
Analyst Price Targets (4 )
Broker Rating
Arbutus Biopharma currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, four are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/2/2024 | JMP Securities | Roy Buchanan | Strong Buy | Strong Buy |
6/6/2024 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
6/5/2024 | Chardan Capital Markets | Keay T Nakae | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 4 |
Average Target Price | $5.25 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.10 |
ABUS FAQs
Arbutus Biopharma Corporation (ABUS) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 4 brokerage firms.
The average price target for Arbutus Biopharma Corporation (ABUS) is $5.25. The current on short-term price targets is based on 3 reports.
The forecasts for Arbutus Biopharma Corporation (ABUS) range from a low of $4 to a high of $7. The average price target represents a increase of $30.60 from the last closing price of $4.02.
The current UPSIDE for Arbutus Biopharma Corporation (ABUS) is 30.60%
Based on short-term price targets offered by four analysts, the average price target for Arbutus Biopharma comes to $5.25. The forecasts range from a low of $4.00 to a high of $7.00. The average price target represents an increase of 26.81% from the last closing price of $4.14.